Product Description
Mechanisms of Action: CYP51A1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Vaginal
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | France | Greece | Hong Kong | Hungary | India | Ireland | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Mexico | Morocco | Netherlands | Pakistan | Peru | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | South Africa | Spain | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Kaifeng Pharmaceutical (Group)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Candidiasis, Vulvovaginal
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CTR20130250 | P1 |
Active, not recruiting |
Candidiasis, Vulvovaginal |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
| CTR20131279 | P2 |
Recruiting |
Candidiasis, Vulvovaginal |
None |
2025-04-29 |
Treatments |
|
| CTR20130309 | P2 |
Active, not recruiting |
Candidiasis, Vulvovaginal |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
| CTR20170167 | P3 |
Recruiting |
Candidiasis, Vulvovaginal |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |